The Centre may consider granting indemnity or legal protection to US drugmakers such as Pfizer and Moderna to rollout their vaccines in India. Pfizer is seeking the indemnity bond that will exempt it from any action in case its vaccine causes side effects among the people who receive it in India. Moreover, the government’s drive will largely be propelled by domestic manufacturers augmenting their production lines. The government is looking to companies that are manufacturing vaccines in India because of the logistics and affordability factor.